We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

C-reactive Protein Varies According to Genetic Heritage

By LabMedica International staff writers
Posted on 20 Oct 2010
Print article
C-reactive protein is found in the blood and the levels rise in response to inflammation and is linked to a higher risk for heart disease.

Even though high C-reactive protein (CRP) blood levels have been associated with a greater chance of developing heart disease, the link is uncertain if the association is casual. It is synthesized by the liver in response to factors released by adipocytes (fat cells). Scientists are not sure whether the CRP-lowering effects of statins have any health benefits.

In a study, carried out at the University College London (UCL; London, UK), investigators examined data on 221,287 individuals from 89 published studies. The risk cut-off point used was 2 mg/L based on the findings of the US Food and Drug Administration (FDA; Silver Spring, MD, USA) for males over 50 and females over 60 who have one other heart disease risk factor as well as CRP values over the this level.

The scientists found that CRP blood levels vary according to ethnicity, even after such factors as age and body mass index (BMI) has been taken into account. They found the following geometric mean CRP levels according to ancestry: 2.6 mg/L in 18,585 African-Americans; 2.51 mg/L in 5,049 Hispanics; 2.34 mg/L in 1,053 South Asians; 2.03 mg/L in 104,949 Caucasians; and 1.01 mg/L in 39,521 East Asians. The order remained unchanged when the investigators calculated the probability that individuals in each ethnic group would exceed the 2 mg/L CRP threshold at any age. Over 50% of Hispanics and African-Americans were over the 2 mg/L CRP threshold at the age of 50, compared to fewer than half of East Asians. At the age of 60 under 40% of East Asians and nearly two-thirds of African-Americans and Hispanics would likely have a CRP greater than 2 mg/L.

Tina Shah, Ph.D., coauthor of the study, noted that, "The difference in average population CRP values in populations of different ancestry are sufficiently large as to have bearing on clinical management and statin eligibility based on single CRP cut-off point values." The study was published online on September 28, 2010 in Circulation: Cardiovascular Genetics.

Related Links:
University College London
FDA


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.